Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations
News
Lynparza (olaparib) has been recommended for approval in the European Union to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA1 and BRCA2, two DNA repair genes. The marketing authorization application ... Read more